Key China COVID-19 examination delivered results that affected ensuing exploration on Covid Kumar Jeetendra | September 18, 2020 Crucial China COVID-19 study produced results that Affected subsequent research on coronavirus Early in the start of the COVID-19 pandemic, a small study in China produced results that affected subsequent research on the virus. Researchers at the University of Cincinnati used the same research parameters on a much larger patient population and reached completely different …
Effect of Discreet Monsoon on Dengue Epidemiology Kumar Jeetendra | September 17, 2020 The arrival Mosquitoes and Dengue with the seasonal rains are pivotal in understanding the pathogenesis of the virus in tropical medicine. Dengue has been a resonant feature in the Indian subcontinent making epidemic outbreaks in the last 4 decades, but it was in the last decade that the diagnosis of the virus took the impetus …
US intends to convey COVID-19 immunization following approval Kumar Jeetendra | September 16, 2020 The US government plans to start distributing a COVID-19 vaccine within one day of any regulatory authorization, an official from the research said on September 16. Government officials also said the US Centers for Disease Control and Prevention will decide how initial, limited vaccine doses will be allocated and distributed.
A few immunosuppressants don’t build COVID-19 risk: Scientists Kumar Jeetendra | September 15, 2020 Therapeutics which suppress the immune system in people who have inflammatory diseases like psoriasis and rheumatoid arthritis”are not associated with a significantly greater risk” for contracting COVID-19, according to a study which says these patients should continue taking their medicine as prescribed. Dermatology researchers in the Henry Ford Health System in the US, which treats …
PC planned antiviral proteins restrain COVID-19 in lab, researchers find Kumar Jeetendra | September 14, 2020 Computer-designed synthetic antiviral proteins have been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19, scientists say. From the experiments, the lead antiviral candidate, called LCB1, rivalled the best-known SARS-CoV-2 neutralising antibodies in its protective activities, according to the findings published in the journal Science. The researchers at the University of …
Asia offers more influenza shots to take off COVID-19 difficulties Kumar Jeetendra | September 14, 2020 Some Asian countries are rolling out early and more competitive influenza vaccination programs this year, seeking to decrease the capacity of people contracting the flu and COVID-19 simultaneously, crippling health care systems. With a second or third wave of the coronavirus pandemic looming for many countries, tackling this year’s flu season – typically December through …
DCGI orders Serum Institute of India to suspend enrollment for Oxford COVID-19 immunization preliminaries Kumar Jeetendra | September 12, 2020 Drugs Controller General of India (DCGI) has led Serum Institute of India to suspend until further orders new recruitment in stage 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate in the backdrop of pharma giant AstraZeneca pausing the trials in different countries. In an order, a copy of which was obtained by …
Bharat Biotech States Covaxin generated Strong immune response in monkeys Kumar Jeetendra | September 12, 2020 Bharat Biotech announced its prospective COVID-19 vaccine — Covaxin — was discovered to generate strong immune responses in rhesus macaques or monkeys, preventing infection and disease even upon high levels of exposure to live SARS-CoV-2 virus. The Hyderabad-based firm said data from the study on primates substantiate the immunogenicity of the vaccine candidate. Covaxin developed …
Dr. U S Vishal Rao shares deeper insights into the ICMR PLACID trial research on plasma therapy Kumar Jeetendra | September 11, 2020 Bengaluru, 11th September 2020 – The recent study conducted by the Indian Council of Medical Research (ICMR) stated that using plasma therapy for COVID-19 claims that the therapy neither reduces the death risk nor does it slow down the disease’s progression from mild to severe stage. HealthCare Global Enterprises Limited (HCG) – largest cancer care …
Study surveys ongoing bits of knowledge into the pathogenesis of feline leukemia virus contamination Kumar Jeetendra | September 10, 2020 Feline leukemia virus (FeLV) is a gammaretrovirus that occurs worldwide in domestic cats, in addition to small wild cats. It’s associated with various severe, and sometimes fatal, diseases including anaemia, immunosuppression and certain cancers. First described over 55 years ago, FeLV has been the topic of intense research interest, which has led to increasingly robust …
China favors first nasal spray COVID-19 antibody for preliminaries Kumar Jeetendra | September 10, 2020 China has approved for trials its initial nasal spray vaccine to combat the novel coronavirus that has claimed over 904,000 lives and infected more than 27 million people globally, official media here reported on September 10. China’s only nasal spray vaccine against the coronavirus is anticipated to start phase I clinical trials in November, and …
CRISPR-based framework smothers qualities identified with AAV antibody production Kumar Jeetendra | September 9, 2020 Gene therapy generally is based on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In the event of CRISPR-based gene therapies, molecular scissors can then snip out a faulty gene, add in a missing arrangement or enact a temporary change in its expression, but the body’s immune response to AAV can …
